Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
申请人:Cytovia, Inc.
公开号:US20030069239A1
公开(公告)日:2003-04-10
The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I:
1
wherein A, Ar
1
, Ar
2
, R
1
and R
3
are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
[EN] 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] 2, 6-BISHETEROARYL-4-AMINOPYRIMIDINES UTILISEES EN TANT QU'ANTAGONISTES DES RECEPTEURS DE L'ADENOSINE
申请人:ALMIRALL PRODESFARMA SA
公开号:WO2005058883A1
公开(公告)日:2005-06-30
4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R1 and R2 are adenosine A2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.
Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
申请人:Cytovia, Inc.
公开号:US20040097503A1
公开(公告)日:2004-05-20
The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I:
1
wherein A, Ar
1
, Ar
2
, R
1
and R
3
are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
申请人:Crespo Crespo Maria Isabel
公开号:US20080058356A1
公开(公告)日:2008-03-06
4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R
1
and R
2
are adenosine A
2A
receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.